Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Mini Oral - NSCLC, metastatic

LBA59 - First-line nivolumab (NIVO) + ipilimumab (IPI) combined with 2 cycles of platinum-based chemotherapy (chemo) vs 4 cycles of chemo in advanced non-small cell lung cancer (NSCLC): Patient-reported outcomes (PROs) from CheckMate 9LA

Date

18 Sep 2020

Session

Mini Oral - NSCLC, metastatic

Presenters

Martin Reck

Citation

Annals of Oncology (2020) 31 (suppl_4): S1142-S1215. 10.1016/annonc/annonc325

Authors

M. Reck1, T. Ciuleanu2, M. Cobo3, M. Schenker4, B. Zurawski5, J. Menezes6, E. Richardet7, J. Bennouna8, Y. Cheng9, L. Paz-Ares10, S. Lu11, T. John12, B. Padilla13, X. Sun13, A. Moisei13, J. Yan14, Y. Yuan15, S.I. Blum15, D.P. Carbone16

Author affiliations

  • 1 Department Of Thoracic Oncology, Airway Research Center North, German Center for Lung Research, LungClinic, 22927 - Grosshansdorf/DE
  • 2 Medical Oncology Department, Institutul Oncologic Prof. Dr. Ion Chiricuta and UMF Iuliu Hatieganu, Cluj-Napoca/RO
  • 3 Medical Oncology Department, Hospital Carlos Haya De Malaga, Malaga/ES
  • 4 Medical Oncology Department, Sf. Nectarie Oncology Center, Craiova/RO
  • 5 Chemotherapy Ambulatory, Ambulatorium Chemioterapii, Bydgoszcz/PL
  • 6 Department Of Clinical Oncology, Hospital Nossa Senhora Da Conceição, Porto Alegre/BR
  • 7 Oncology Department, Instituto Oncológico De Córdoba, Córdoba/AR
  • 8 Thoracic Oncology Unit, University Hospital of Nantes, Nantes/FR
  • 9 Department Of Thoracic Oncology, Jilin Cancer Hospital, Changchun/CN
  • 10 Department Of Medical Oncology, Hospital Universitario 12 de Octubre, CNIO-H12o Lung Cancer Unit, Universidad Complutense & CiberOnc, Madrid/ES
  • 11 Oncology Department, Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai JiaoTong University, Shanghai/CN
  • 12 Department Of Medical Oncology, Austin Hospital, Heidelberg/AU
  • 13 Patient-centered Outcomes, Adelphi Values, Boston/US
  • 14 Global Clinical Development, Bristol-Myers Squibb Company, Princeton/US
  • 15 Worldwide Health Economics & Outcomes Research, Bristol-Myers Squibb Company, Princeton/US
  • 16 Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus/US
More

Resources

Login to access the resources on OncologyPRO.

Abstract LBA59

Background

CheckMate 9LA (NCT03215706), a phase III randomized study, met its primary endpoint of improved overall survival with NIVO 360 mg Q3W + IPI 1 mg/kg Q6W + 2 cycles of chemo (n = 361) vs 4 cycles of chemo (n = 358) in patients (pts) with treatment-naive, stage IV/recurrent NSCLC and no known sensitizing EGFR/ALK alterations. We present PROs from the study.

Methods

PROs were exploratory endpoints; disease-related symptoms were evaluated using the Lung Cancer Symptom Scale average symptom burden index and 3-item global index (LCSS ASBI/3-IGI); health-related quality of life (HRQoL) was evaluated using EQ-5D-3L visual analog scale and utility index (EQ-5D-3L VAS/UI). Analyses included mean changes from baseline, mixed-effect model repeated measures (MMRM) of longitudinal changes, and time to deterioration.

Results

PRO completion rates were > 80% across arms for most on-treatment assessment time points in which there were ≥ 10 pts (up to week 90 for NIVO + IPI + chemo and week 78 for chemo). A trend for improvement in LCSS ASBI and 3-IGI was seen in both treatment arms, though the minimally important difference was not reached. In both arms, mean EQ-5D-3L VAS scores approached UK population norms after ∼30 weeks. MMRM analyses showed similar improvement across arms in overall LCSS ASBI when there was a sufficient number of patients in both study arms for assessment (up to week 78). There was a decreased risk of, and delayed time to, definitive deterioration with NIVO + IPI + chemo vs chemo (Table).

Conclusions

Pts with advanced NSCLC treated with NIVO + IPI + chemo (2 cycles) maintained their quality of life as compared with chemo (4 cycles). Pts in the NIVO + IPI + chemo arm had decreased risk of definitive deterioration in HRQoL and symptoms vs chemo. Table: LBA59

Time to deterioration with NIVO + IPI + chemo (2 cycles) vs chemo (4 cycles)

HRa (95% CI)
Time to first deteriorationb
LCSS ASBI 1.16 (0.91–1.48)
LCSS 3-IGI 1.10 (0.89–1.36)
EQ-5D-3L VAS 1.07 (0.88–1.30)
EQ-5D-3L UId 0.88 (0.72–1.07)
Time to definitive deterioration c
LCSS ASBI 0.66 (0.47–0.92)
LCSS 3-IGI 0.66 (0.50–0.88)
EQ-5D-3L VAS 0.73 (0.58–0.93)
EQ-5D-3L UId 0.72 (0.57–0.90)

Includes on-treatment and follow-up. aHR < 1 favors NIVO + IPI + chemo over chemo. bTime from randomization to when change in PRO score first meets/exceeds deterioration threshold. cIn addition to initial assessment, all subsequent assessments must meet/exceed the threshold. dBased on UK norms.

Clinical trial identification

NCT03215706.

Editorial acknowledgement

Professional writing assistance was provided by Laura Yee, of Caudex, funded by Bristol-Myers Squibb Company.

Legal entity responsible for the study

Bristol-Myers Squibb Company.

Funding

Bristol-Myers Squibb Company.

Disclosure

M. Reck: Advisory/Consultancy, Travel/Accommodation/Expenses: Abbvie; Advisory/Consultancy, Travel/Accommodation/Expenses: Amgen; Advisory/Consultancy, Travel/Accommodation/Expenses, Speaker Bureau/Expert testimony: AstraZeneca; Advisory/Consultancy, Travel/Accommodation/Expenses, Speaker Bureau/Expert testimony, Research grant/Funding (institution): Bristol Myers Squibb; Advisory/Consultancy, Travel/Accommodation/Expenses, Speaker Bureau/Expert testimony, Research grant/Funding (institution): Boehringer-Ingelheim; Advisory/Consultancy, Travel/Accommodation/Expenses, Speaker Bureau/Expert testimony: Lilly; Advisory/Consultancy, Travel/Accommodation/Expenses, Speaker Bureau/Expert testimony: Merck; Advisory/Consultancy, Travel/Accommodation/Expenses, Speaker Bureau/Expert testimony: MSD; Advisory/Consultancy, Travel/Accommodation/Expenses, Speaker Bureau/Expert testimony: Novartis; Advisory/Consultancy, Travel/Accommodation/Expenses, Speaker Bureau/Expert testimony: Pfizer; Advisory/Consultancy, Travel/Accommodation/Expenses, Speaker Bureau/Expert testimony: Roche; Advisory/Consultancy: Samsung. T-E. Ciuleanu: Advisory/Consultancy, Travel/Accommodation/Expenses: Astella Pharma; Advisory/Consultancy, Travel/Accommodation/Expenses: Janssen; Advisory/Consultancy, Travel/Accommodation/Expenses: Bristol Myers Squibb; Advisory/Consultancy, Travel/Accommodation/Expenses: Merck Serono; Advisory/Consultancy, Travel/Accommodation/Expenses: Amgen; Advisory/Consultancy, Travel/Accommodation/Expenses: Roche; Advisory/Consultancy, Travel/Accommodation/Expenses: Pfizer; Advisory/Consultancy, Travel/Accommodation/Expenses: MSD; Advisory/Consultancy, Travel/Accommodation/Expenses: Servier; Advisory/Consultancy, Travel/Accommodation/Expenses: Ipsen; Advisory/Consultancy, Travel/Accommodation/Expenses: AD Pharma; Advisory/Consultancy, Travel/Accommodation/Expenses: AstraZeneca; Advisory/Consultancy, Travel/Accommodation/Expenses: Lilly; Advisory/Consultancy, Travel/Accommodation/Expenses: Novartis. M. Schenker: Research grant/Funding (self, related to the current clinical trial), Research grant/Funding (institution, related to the current clinical trial): Bristol Myers Squibb; Research grant/Funding (self, not related to the current clinical trial), Research grant/Funding (institution, not related to the current clinical trial): MSD; Research grant/Funding (self, not related to the current clinical trial), Research grant/Funding (institution, not related to the current clinical trial): AstraZeneca; Research grant/Funding (self, not related to the current clinical trial), Research grant/Funding (institution, not related to the current clinical trial): Pfizer; Research grant/Funding (self, not related to the current clinical trial), Research grant/Funding (institution, not related to the current clinical trial): Regeneron; Research grant/Funding (self, not related to the current clinical trial), Research grant/Funding (institution, not related to the current clinical trial): Novartis; Research grant/Funding (self, not related to the current clinical trial), Research grant/Funding (institution, not related to the current clinical trial): Roche; Research grant/Funding (self, not related to the current clinical trial), Research grant/Funding (institution, not related to the current clinical trial): Astellas; Research grant/Funding (self, not related to the current clinical trial), Research grant/Funding (institution, not related to the current clinical trial): AbbVie; Research grant/Funding (self, not related to the current clinical trial), Research grant/Funding (institution, not related to the current clinical trial): Bayer; Research grant/Funding (self, not related to the current clinical trial), Research grant/Funding (institution, not related to the current clinical trial): Eli Lilly; Research grant/Funding (self, not related to the current clinical trial), Research grant/Funding (institution, not related to the current clinical trial): Merck Serono; Research grant/Funding (self, not related to the current clinical trial), Research grant/Funding (institution, not related to the current clinical trial): Gilead; Research grant/Funding (self, not related to the current clinical trial), Research grant/Funding (institution, not related to the current clinical trial): Amgen. B. Zurawski: Honoraria (self), Speaker Bureau/Expert testimony: Bayer; Honoraria (self), Speaker Bureau/Expert testimony: Astellas; Honoraria (self), Speaker Bureau/Expert testimony: MSD; Honoraria (self), Speaker Bureau/Expert testimony: Bristol Myers Squibb; Honoraria (self): Janssen Cilag; Honoraria (self): AstraZeneca. J. Bennouna: Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: AstraZeneca; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: Roche; Honoraria (self), Advisory/Consultancy: Bristol Myers Squibb; Honoraria (self), Advisory/Consultancy: Boehringer Ingelheim; Honoraria (self), Advisory/Consultancy: MSD; Honoraria (self), Advisory/Consultancy: Servier; Honoraria (self), Advisory/Consultancy: Bayer. L. Paz-Ares: Honoraria: Adacap; Honoraria: Amgen; Honoraria, Research grant/Funding: AstraZeneca; Honoraria: Bayer; Honoraria, Blueprint Medicines; Honoraria, Boehringer Ingelheim; Honoraria, Research grant/Funding: Bristol Myers Squibb; Honoraria: Celgene; Honoraria: Eli Lilly; Honoraria: Incyte; Honoraria: Ipsen; Honoraria, Research grant/Funding: Merck Sharp and Dohme; Honoraria: Novartis; Honoraria, Research grant/Funding: Pfizer; Honoraria: PharmaMar; Honoraria: Roche; Honoraria: Sanofi; Honoraria: Servier; Honoraria: Sysmex; Honoraria: Takeka; Leadership role: Altum sequencing; Officer/Board of Directors: Genómica. S. Lu: Advisory/Consultancy, Speaker bureau/Expert testimony, Research grant/Funding (self): AstraZeneca; Advisory/Consultancy: Boehringer Ingelheim; Research grant/Funding (self): Bristol Myers Squibb; Research grant/Funding (self): Heng Rui; Advisory/Consultancy, Research grant/Funding (self): Hutchison Medipharma; Advisory/Consultancy: Simcere; Advisory/Consultancy: ZaiLab; Advisory/Consultancy: GenomiCare; Advisory/Consultancy, Speaker bureau/Expert testimony, Research grant/Funding (self): Roche; Speaker bureau/Expert testimony: Hansoh. T. John: Honoraria (self), Advisory/Consultancy: Bristol Myers Squibb; Honoraria (self), Advisory/Consultancy: AstraZeneca; Honoraria (self), Advisory/Consultancy: Roche; Honoraria (self), Advisory/Consultancy: Merck; Honoraria (self), Advisory/Consultancy: MSD; Honoraria (self), Advisory/Consultancy: Boehringer Ingelheim; Honoraria (self), Advisory/Consultancy: Bayer; Advisory/Consultancy: Takeda; Honoraria (institution): Specialised Therapeutics; Honoraria (institution): Pfizer; Honoraria (institution): Novartis. B. Padilla, X. Sun, A. Moisei: Full-time employment: Adelphi Values. J. Yan, Y. Yuan: Full-time employment: Bristol Myers Squibb. S.I. Blum: Full-time employment, Stockholder: Bristol Myers Squibb. D.P. Carbone: Honoraria (self), Advisory/Consultancy, Travel/Accommodation/ Expenses: AstraZeneca; Honoraria (self): Nexus Oncology; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: Bristol-Myers Squibb; Honoraria (institution), Advisory/Consultancy, Travel/Accommodation/Expenses: Merck; Advisory/ Consultancy, Travel/Accommodation/Expenses: AbbVie; Leadership role: The Ohio State University; Leadership role: ASCO and AACR; Leadership role: NCI; Leadership role: Eastern Cooperative Oncology Group and the Thoracic Core committees for both the Alliance and ECOG/ACRIN; Leadership role, Past president: International Association for the Study of Lung Cancer (IASLC); Leadership role: Damon Runyon, K08, ASCO, AACR, CDA, LIFE and IDEA; Leadership role, Leader: Vanderbilt CCC’s Host-Tumor Interactions and Thoracic/Head and Neck Programs; Leadership role: Vanderbilt Lung Cancer SPORE, and an NCI U01 consortium; Officer/ Board of Directors: IASLC, LCFA, LUNGevity, ALCMI, Joan’s Legacy Foundation, Lance Armstrong Foundation, Wendy Wyrick Foundation, Wendy Will Case Foundation, Jack Roth Foundation; Full/ Part-time employment, Professor of Medicine: The Ohio State University Comprehensive Cancer Center; Advisory/Consultancy, Travel/Accommodation/Expenses: EMD Serono; Advisory/Consultancy, Travel/Accommodation/Expenses: Inviata; Advisory/Consultancy, Travel/Accommodation/Expenses: Inovio; Advisory/Consultancy, Travel/Accommodation/Expenses: Janssen; Advisory/Consultancy, Travel/Accommodation/Expenses: Loxo Oncology; Advisory/Consultancy, Travel/Accommodation/ Expenses: Merck, Sharp & Dohme; Honoraria (self), Advisory/Consultancy, Travel/ Accommodation/Expenses: Pfizer; Advisory/Consultancy, Travel/Accommodation/Expenses: Roche/ Genentech; Advisory/Consultancy, Travel/Accommodation/Expenses: Takeda Oncology; Advisory/ Consultancy, Travel/Accommodation/Expenses: Trinity; Advisory/Consultancy, Travel/Accommodation/ Expenses: Incyte; Advisory/Consultancy, Travel/Accommodation/Expenses: Kyowa Kirin; Advisory/ Consultancy, Travel/Accommodation/Expenses: Novartis; Advisory/Consultancy, Travel/ Accommodation/Expenses: Gritstone Oncology; Advisory/Consultancy, Travel/Accommodation/Expenses: GlaxoSmithKline; Advisory/Consultancy, Travel/Accommodation/Expenses: Roche China; Advisory/Consultancy, Travel/Accommodation/Expenses: GenePlus; Advisory/Consultancy, Travel/ Accommodation/Expenses: Daiichi Sankyo Inc; Advisory/Consultancy: Seattle Genetics, GI Therapeutics (Intellisphere), Gloria Biosciences. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings